A Vancouver-based research team led by Canada’s most cited neuroscientist, Dr. Patrick McGeer, has successfully carried out studies suggesting that, if started early enough, a daily regimen of the non-prescription NSAID (nonsteroidal anti-inflammatory drug) ibuprofen can prevent the onset of Alzheimer’s disease.
This means that by taking an over-the-counter medication, people can ward off a disease that, according to Alzheimer’s Disease International’s World Alzheimer Report 2016, affects an estimated 47 million people worldwide, costs health care systems worldwide more than US$818 billion  per year and is the fifth leading cause of death in those aged 65 or older.
The Alzheimer’s Association estimates that there are more than 5 million cases in the United States alone, with a new case being identified every 66 seconds. The annual cost to the country in 2017 is estimated have been US$259 billion, with that figure predicted to potentially rise to US$1.1 trillion  by 2050.
Dr. McGeer, who is President and CEO of Vancouver-based Aurin Biotech, and his wife, Dr. Edith McGeer, are among the most cited neuroscientists in the world. Their laboratory is world-renowned for their 30 years of work in neuroinflammation and neurodegenerative diseases, particularly Alzheimer’s disease. A paper detailing Dr. McGeer’s most recent discoveries has been published in the prestigious Journal of Alzheimer’s Disease.
In 2016, Dr. McGeer and his team announced that they had developed a simple saliva test that can diagnose Alzheimer’s disease, as well as predict its future onset. The test is based on measuring the concentration of the peptide amyloid-beta protein 42 (Abeta 42) secreted in saliva. In most individuals, the rate of Abeta 42 production is almost exactly the same regardless of sex or age. However, if that rate of production is two to three times higher, those individuals are destined to develop Alzheimer’s disease. That is because Abeta 42 is a relatively insoluble material, and although it is made everywhere in the body, deposits of it occur only in the brain, causing neuroinflammation, which destroys neurons in the brains of people with Alzheimer’s disease.
Contrary to the widely held belief that Abeta 42 is made only in the brain, Dr. McGeer’s team demonstrated that the peptide is made in all organs of the body and is secreted in saliva from the submandibular gland. As a result, with as little as one teaspoon of saliva, it is possible to predict whether an individual is destined to develop Alzheimer’s disease. This gives them an opportunity to begin taking early preventive measures such as consuming non-prescription non-steroidal drugs (NSAIDs) such as ibuprofen.
“What we’ve learned through our research is that people who are at risk of developing Alzheimer’s exhibit the same elevated Abeta 42 levels as people who already have it; moreover, they exhibit those elevated levels throughout their lifetime so, theoretically, they could get tested anytime,” says Dr. McGeer. “Knowing that the prevalence of clinical Alzheimer’s Disease commences at age 65, we recommend that people get tested ten years before, at age 55, when the onset of Alzheimer’s would typically begin. If they exhibit elevated Abeta 42 levels then, that is the time to begin taking daily ibuprofen to ward off the disease.
“Unfortunately, most clinical trials to date have focused on patients whose cognitive deficits are already mild to severe, and when the therapeutic opportunities in this late stage of the disease are minimal. Consequently, every therapeutic trial has failed to arrest the disease’s progression. Our discovery is a game changer. We now have a simple test that can indicate if a person is fated to develop Alzheimer’s disease long before it begins to develop. Individuals can prevent that from happening through a simple solution that requires no prescription or visit to a doctor. This is a true breakthrough since it points in a direction where AD can eventually be eliminated.”
The Latest on: Alzheimer’s disease
via Google News
The Latest on: Alzheimer’s disease
- From 6th grader to lawmakers, an effort to cure Alzheimer's in Texas on April 17, 2019 at 4:16 pm
(Courtesy: Machado family) AUSTIN (Nexstar) — Hundreds of thousands of Texans face Alzheimer's disease diagnoses. Advocates want the state to fund more research and education for the disease. They ... […]
- To fight Alzheimer’s disease, Univ. of Washington researchers target plaque-causing proteins | GeekWire on April 17, 2019 at 3:47 pm
Editor's note: the video above was first created in March 2019. Researchers at the University of Washington have created a molecule that aims to stop the formation of protein clusters thought to be a ... […]
- Can NSAIDs prevent Alzheimer's disease? on April 17, 2019 at 2:32 pm
PLAINS TOWNSHIP, LUZERNE COUNTY (WBRE/WYOU) - The impact of Alzheimer's disease is absolutely devastating. It wipes away people's memories and causes great pain for those who watch their loved ones ... […]
- Alzheimer’s Disease Therapeutics and Diagnostics Market Analysis 2019 Forecasts To 2024 | Namenda, Aricept, Exelon, Solanezumab on April 16, 2019 at 11:07 pm
Wiseguyreports.Com Adds “Alzheimer’s Disease Therapeutics and Diagnostics -Market Demand, Growth, Opportunities and Analysis Of Top Key Player Forecast To 2024” To Its Research Database Population ... […]
- To fight Alzheimer’s disease, Univ. of Washington researchers target plaque-causing proteins on April 16, 2019 at 4:31 pm
Researchers developed a synthetic peptide to stop the formation of protein clusters that are thought to cause cognitive problems in patients with Alzheimer’s disease. (University of Washington Photo) ... […]
- Alzheimer's Disease Diagnostic Market Expects to Worth Over $12 Bn by Renowned Players and Business Insights to 2022 on April 16, 2019 at 3:07 pm
Apr 16, 2019 (AB Digital via COMTEX) -- Global Alzheimer's Disease Diagnostic Market is anticipated to project remarkable expansion at a CAGR of 10% during the forecast period of 2018-2022 ... […]
- Hal Ketchum Is Suffering From Alzheimer’s Disease, Wife Reveals on April 16, 2019 at 7:24 am
Hal Ketchum, known for his '90s hits including "Past the Point of Rescue" and "Small Town Saturday Night, " has been revealed to be suffering from Alzheimer's Disease and can no longer go out on ... […]
- Alzheimer’s Disease Toxicity Halted by Synthetic Peptides on April 16, 2019 at 7:00 am
Alzheimer’s disease (AD) is characterized by the formation of large, insoluble deposits, or plaques, of amyloid-β peptide (Aβ) in the brain. These plaques are generated by the aggregation of smaller, ... […]
- A New Tool Developed At FAU Is Measuring Knowledge Of Alzheimer's Disease In Rural Areas on April 15, 2019 at 7:42 pm
Alzheimer’s disease is the sixth leading cause of death in the U.S., impacting an estimated 5.8 million Americans who currently live with the disease. Many of them are 65 and older and live in places ... […]
via Bing News